Thanksgiving stocks to watch: DAL, BUD, DIS ... >>> READ MORE

How to Know if You Should Buy, Sell or Hold Pfizer Inc.

PFE stock has plenty going for it - if that's what you want

Why It's Time to Put PFE Stock on Your Watchlist

Source: Shutterstock

    View All  

Every once in awhile, someone will ask me what’s a good stock to buy. That is a loaded question if there ever was one. I usually say it depends on what they hope to achieve by owning it. That’s not a cop-out. Rather, it’s a way to determine if they’re looking to hit a home run or a comfortable single. Pfizer Inc. (NYSE:PFE) and PFE stock is a good example of this.

 Depending on what you’re looking to accomplish by investing in Pfizer,  I’ll have a better idea whether you should buy, sell or hold.

PFE Stock’s Beauty in Eye of Beholder

I’ll start with existing shareholders who already own Pfizer stock.

If you had owned Pfizer since the market bottom in March 2009, you’ve done astronomically well on your investment. On a calendar-year basis, you haven’t had a down year since then. And 2017 is shaping up to be the first year with a total return in double digits — up 12.3% through November 10 — since 2013.

That’s the good news.

The bad news is PFE stock hasn’t kept up with either the S&P 500 or its Big Pharma peers over the past decade.

So, beauty is in the eye of the beholder.

Sell or Hold PFE Stock

Recently, InvestorPlace’s Lawrence Meyers highlighted the reasons Pfizer might be turning a corner, moving from a slow grower to something a little more robust.

“Big pharma has really struggled over the past several years, and I think that dividend investors have been seduced by their strong cash flow without ever realizing the stocks are wildly overvalued,” Meyers wrote November 2. “Pfizer Inc. reported lousy third-quarter earnings on Tuesday, but that doesn’t mean the stock is priced for such blah results.”

Analysts expect Pfizer to earn $2.75 in 2018 and $2.86 in 2019; that’s a forward P/E of 12.3, much lower than its five-year average of 22.3. That’s not so wildly overvalued.

However, take a look back at both its price-to-sales and price-to-cash-flow ratios over the past five years. Those show a stock that is more expensive today than at almost any time in the past decade.

Meyers’ assessment that it has turned the corner is likely right on the money. However, you won’t know for sure until late next year or early in 2019. That means you better be prepared to accept the $1.28 per-share dividend — likely $1.36 in 2018 and $1.44 in 2019 — and not much else.

If you’re good with that, I wouldn’t sell.

I’d continue to hold because with more than $13 billion in free-cash flow (that’s where dividends are paid from) over the trailing 12 months and an FCF yield of 5.5% ($13.2B FCF / $239B enterprise value), which isn’t too shabby in the ninth year of a bull market, you’ve got a very solid company on your hands.

Buy Pfizer Stock

In this scenario, you don’t currently own PFE stock but are considering buying it. Again, it depends on the reasons you want to own it.

If you don’t have a healthcare stock in your portfolio, you might want to look beyond the pharmaceutical industry. Look for potential candidates with more immediate growth prospects.

Next Page

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC